This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
This week, we will discuss the fresh-off-the-press trials from this week’s issue of the NEJM: PERL and CKD-FiX. These two trials examined if the uric acid and CKD link is causal: by measuring CKD progression after giving patients allopurinol. Be ready for another medical reversal.
This week, we discuss the latest from CRIC, an examination of NSAIDs versus opioids for patients with CKD. Join us May 12 and 13th to discuss with #NephJC.
This week, we will not discuss anything related to COVID. We know cardiovascular disease is the cause of most morbidity and mortality in CKD. Can an invasive approach benefit our patients?